Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Presents New Data at AASLD Examining the Effects of Ocaliva® (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC
Poster presentations explore changes in biochemical markers of disease progression in PBC patients with cirrhosis and renal impairment
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Net Ocaliva ® (obeticholic acid or OCA) 3Q sales of $4.7 million Positive opinion adopted by Committee of Medicinal Products in Human Use (CHMP) for Ocaliva in Primary Biliary Cholangitis (PBC) in EU Enrollment in Phase 2 CONTROL trial complete in Nonalcoholic Steatohepatitis (NASH) patients with
View HTML
Toggle Summary Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting
Intercept will collaborate with academic leaders on a new NASH patient registry
View HTML
Toggle Summary Intercept to Report Third Quarter 2016 Financial Results on November 3
NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its third quarter 2016
View HTML
Toggle Summary Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
NEW YORK, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the European Medicines
View HTML
Toggle Summary Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis
New Drug Submission filed to Health Canada for obeticholic acid for PBC Submission granted priority review If approved, obeticholic acid would represent first new treatment option for PBC in 20 years                           NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals,
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conferences
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the
View HTML
Toggle Summary New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC
NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the New England Journal of Medicine
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Ocaliva ® (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016 Net Ocaliva 2Q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenue REGENERATE NASH trial targeted to complete enrollment for interim analysis in 1H17 Conference
View HTML
Toggle Summary Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
NEW YORK, July 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016
View HTML